Our site is currently under maintenance. We apologize for any issues this may cause.
Mydecine Innovations Group—A biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD.
By combining cutting-edge technology, drug development infrastructure, and artificial intelligence, Mydecine is creating novel therapeutic options in fields with significant unmet needs. Our multinational team is making great strides on a pipeline of novel compounds, regulated drug delivery systems, and treatments that include the next generation of psychedelic molecules.
Mydecine's mission is to become a trusted source of safe and effective medication-based treatments to address the unmet needs for mental health and addiction disorders.
Through technology and research, our vision is to become the number one globally trusted leader in treating mental health and addiction disorders. We see success when all medical and therapy communities view psychedelic medicine as an accepted and adopted form of treatment offered in our existing healthcare infrastructure.
Sign up to receive the latest on Mydecine